share_log

HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

Benzinga ·  Mar 17 12:53

HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma (NASDAQ:STRO) from Buy to Neutral and lowers the price target from $12 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 370

Recommended

Write a comment